Thursday May 25th 2017

Archive for June, 2011

MS sufferer happy with government announcement

MS sufferer happy with government announcement

Karen Torrie-Racine was “thrilled” to hear the federal government has agreed to fund clinical trials of a controversial multiple sclerosis treatment called chronic cerebrospinal venous insufficiency. “Like everyone, I’m just really anxious for the [Read More]

MS vein therapy trial decision ‘unexpected’

MS vein therapy trial decision ‘unexpected’

The federal government’s decision to hold clinical trials for an experimental multiple sclerosis treatment is getting a mixed reaction. Health Minister Leona Aglukkaq announced on Wednesday that Ottawa will launch early stage clinical trials into using angioplasty to [Read More]

Funding ‘liberation’ treatment trials not enough, says Ottawa MS patient

Funding ‘liberation’ treatment trials not enough, says Ottawa MS patient

An Ottawa man who travelled to Poland more than a year ago for a controversial multiple sclerosis treatment says Wednesday’s announcement that Canada will fund clinical trials of the procedure doesn’t go far enough. “While it’s good to see research go forward, this [Read More]

 Page 1 of 10  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]